Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy in Hepatic Metastases of Metastatic Colorectal Cancer: a Phase II Multicentric Study With Patients in Progression After First Line Systemic Chemotherapy

Trial Profile

Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy in Hepatic Metastases of Metastatic Colorectal Cancer: a Phase II Multicentric Study With Patients in Progression After First Line Systemic Chemotherapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
  • Indications Liver metastases
  • Focus Therapeutic Use
  • Acronyms BEVIAC
  • Most Recent Events

    • 11 Oct 2016 Interim results (n=10, data cut off 02/2015) on toxicity and efficacy presented at the 41st European Society for Medical Oncology Congress
    • 25 Nov 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 Nov 2012 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top